Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 12/20 | 0.56 |
| ▸ | CDK2 | P24941 | 11/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100184 | 0.90 | RPS6KA5 (0.54) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL19100396 | 0.78 | CDC7 (0.68) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL19100953 | 0.76 | CDC7 (0.68) | CDC7CDK2RPS6KA5 | |
| SCHEMBL1613026 | 0.75 | CDC7 (0.70) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL19100487 | 0.75 | RPS6KA5 (0.65) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL20548967 | 0.75 | ROCK1 (0.72) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL5659028 | 0.74 | RPS6KA5 (0.68) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL30459871 | 0.74 | RPS6KA5 (0.68) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL19100924 | 0.74 | RPS6KA5 (0.55) | CDC7CDK2RPS6KA5ROCK1MAP3K14 | |
| SCHEMBL20610589 | 0.70 | RPS6KA5 (0.34) | CDC7CDK2RPS6KA5ROCK1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | CDC7 632/4885CDK2 125/4885RPS6KA5 582/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | CDC7 632/4885CDK2 125/4885RPS6KA5 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.